Viatris Inc
VTRSAPI behind this page
VTRS FY 2025 request
Playground key active
/api/financials?ticker=VTRS&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 14,250.4 | 14,692.8 | -3.0% |
Show Product Lines breakouts |
|||
| Amitiza ® | 158.1 | 149.2 | +6.0% |
| Brands | 9,184 | 9,200.3 | -0.2% |
| Brands · Developed Markets | 4,571.2 | 4,731.6 | -3.4% |
| Brands · Emerging Markets | 1,673.6 | 1,567.8 | +6.7% |
| Brands · Greater China | 2,321.8 | 2,156.7 | +7.7% |
| Brands · JANZ | 617.4 | 744.2 | -17.0% |
| Celebrex ® | 272.9 | 285.6 | -4.4% |
| Creon ® | 365.8 | 328.2 | +11.5% |
| Dymista ® | 163.6 | 188 | -13.0% |
| Effexor ® | 257.7 | 252.9 | +1.9% |
| EpiPen® Auto-Injectors | 469.7 | 392 | +19.8% |
| Generics | 5,066.4 | 5,492.5 | -7.8% |
| Generics · Developed Markets | 3,942.8 | 4,197.8 | -6.1% |
| Generics · Emerging Markets | 536.5 | 682.9 | -21.4% |
| Generics · Greater China | 10.7 | 9.8 | +9.2% |
| Generics · JANZ | 576.4 | 602 | -4.3% |
| Influvac ® | 194.4 | 178.7 | +8.8% |
| Lipitor ® | 1,549.3 | 1,468.8 | +5.5% |
| Lyrica ® | 487 | 495.4 | -1.7% |
| Norvasc ® | 709.9 | 673.3 | +5.4% |
| Viagra ® | 408.2 | 395.6 | +3.2% |
| Xalabrands | 158.4 | 166.4 | -4.8% |
| Xanax ® | 139.9 | 145 | -3.5% |
| Yupelri ® | 266.9 | 238.5 | +11.9% |
| Zoloft ® | 254.9 | 235.7 | +8.1% |
Show Business Segments breakouts |
|||
| Developed Markets · Operating Segments | 8,514 | 8,929.4 | -4.7% |
| Emerging Markets · Operating Segments | 2,210.1 | 2,250.7 | -1.8% |
| Greater China · Operating Segments | 2,332.5 | 2,166.5 | +7.7% |
| JANZ · Operating Segments | 1,193.8 | 1,346.2 | -11.3% |
Show Geography breakouts |
|||
| CN | 2,079.8 | 1,911.3 | +8.8% |
| US | 3,006.7 | 3,434.7 | -12.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 14,250.4 | 14,692.8 | -3.0% |
| Other Revenue | 49.5 | 46.5 | +6.5% |
Show Business Segments breakouts |
|||
| Developed Markets · Operating Segments | 38.1 | 32 | +19.1% |
| Emerging Markets · Operating Segments | 7.5 | 9.7 | -22.7% |
| JANZ · Operating Segments | 3.9 | 3.5 | +11.4% |
| Revenue | 14,299.9 | 14,739.3 | -3.0% |
Show Business Segments breakouts |
|||
| Developed Markets · Operating Segments | 8,552.1 | 8,961.4 | -4.6% |
| Emerging Markets · Operating Segments | 2,217.6 | 2,260.4 | -1.9% |
| Greater China · Operating Segments | 2,332.5 | 2,167.8 | +7.6% |
| JANZ · Operating Segments | 1,197.7 | 1,349.7 | -11.3% |
| Cost of Revenue | 9,286.4 | 9,115.7 | +1.9% |
| Gross Profit | 5,013.5 | 5,623.6 | -10.8% |
| Research And Development Expense Excluding Acquired In Process Cost | 965.9 | 808.7 | +19.4% |
| Other Research And Development Expense | 48.3 | 28.3 | +70.7% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 48.3 | 28.3 | +70.7% |
| Selling, General & Administrative | 3,794.1 | 4,104.6 | -7.6% |
| Goodwill Impairment Loss | 2,936.8 | 321 | +814.9% |
Show Business Segments breakouts |
|||
| Developed Markets | 2,261 | — | — |
| Emerging Markets | 375 | — | — |
| Emerging Markets · Disposal Group Heldforsale Not Discontinued Operations | 375 | — | — |
| Europe Segment | -1,554 | — | — |
| JANZ | 300.8 | 321 | -6.3% |
| North America Segment | -707 | — | — |
| Gain Loss Related To Litigation Settlement | -68.5 | 350.9 | -119.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -68.5 | 350.9 | -119.5% |
| Operating Expenses | 7,676.6 | 5,613.5 | +36.8% |
| Operating Income | -2,663.1 | 10.1 | -26467.3% |
| Interest Expense | 471.3 | 550 | -14.3% |
| Other Non-Operating Income (Expense) | 530.6 | 83.3 | +537.0% |
Show Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations breakouts |
|||
| Biocon Biologics | -39.4 | -69.9 | +43.6% |
| Income Before Taxes | -3,665 | -623.2 | -488.1% |
| Income Tax Expense (Benefit) | -150.1 | 11 | -1464.5% |
Show Income Tax Authority breakouts |
|||
| Foreign Country · Ministry Of Finance India | 22.3 | — | — |
| Net Income | -3,514.9 | -634.2 | -454.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | -3,514.9 | -634.2 | -454.2% |
| EPS (Basic) | -3 | -0.53 | -466.0% |
| EPS (Diluted) | -3 | -0.53 | -466.0% |
| Research & Development (FY) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 965.9 | 808.7 | +19.4% |
Show Counterparty Name breakouts |
|||
| Theravance Biopharma · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 57.5 | — | — |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (FY) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Cash Flow Hedging | -29.5 | 54.4 | -154.2% |
| Foreign Exchange Contract · Net Investment Hedging | -6.9 | 9.5 | -172.6% |
| Foreign Exchange Contract · Nondesignated | -321.9 | 225.2 | -242.9% |
| Interest Rate Swap · Cash Flow Hedging | -3.7 | -4.7 | +21.3% |
| Interest Rate Swap · Net Investment Hedging | -57.9 | 20.5 | -382.4% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,322.4 | 734.8 | +80.0% |
| Accounts Receivable | 3,031.3 | 3,221.3 | -5.9% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Variable Consideration | 2,268.6 | 2,536.4 | -10.6% |
| Variable Consideration · Chargebacks | 441.8 | 493.9 | -10.5% |
| Variable Consideration · Governmental rebate programs | 344.1 | 374.7 | -8.2% |
| Variable Consideration · Rebates, promotional programs and other sales allowances | 1,133.2 | 1,266.9 | -10.6% |
| Variable Consideration · Returns | 349.5 | 400.9 | -12.8% |
| Inventory | 3,999.2 | 3,854.1 | +3.8% |
| Prepaid Expenses & Other Current Assets | 1,436.3 | 1,710.5 | -16.0% |
| Total Current Assets | 9,789.2 | 9,520.7 | +2.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,614 | 2,666.1 | -2.0% |
| Goodwill | 6,754.7 | 9,133.3 | -26.0% |
Show Business Segments breakouts |
|||
| Developed Markets | 5,024.5 | 6,752.9 | -25.6% |
| Emerging Markets | 797 | 1,163.8 | -31.5% |
| Greater China | 933.2 | 921.5 | +1.3% |
| Deferred Tax Assets | 1,061.2 | 753 | +40.9% |
| Other Non-Current Assets | 1,871.9 | 2,356.9 | -20.6% |
| Total Assets | 37,193.1 | 41,500.9 | -10.4% |
| Operating Lease Right-of-Use Assets | 271.3 | 253.1 | +7.2% |
| Intangible Assets | 14,396.1 | 16,256.7 | -11.4% |
Show Product Lines breakouts |
|||
| Brands · Developed Markets | 5,656 | 6,464.6 | -12.5% |
| Brands · Emerging Markets | 2,319.2 | 2,583.9 | -10.2% |
| Brands · Greater China | 4,355.3 | 4,779.7 | -8.9% |
| Brands · JANZ | 779.2 | 860.5 | -9.4% |
| Brands · Licensing Agreements | 13,109.7 | 14,688.7 | -10.7% |
| Generics · Developed Markets | 972 | 1,214.6 | -20.0% |
| Generics · Emerging Markets | 141.3 | 160.8 | -12.1% |
| Generics · Greater China | 6.1 | 8.7 | -29.9% |
| Generics · JANZ | 167 | 183.8 | -9.1% |
| Generics · Licensing Agreements | 1,286.4 | 1,567.9 | -18.0% |
Show Business Segments breakouts |
|||
| Developed Markets · Licensing Agreements | 6,628 | 7,679.2 | -13.7% |
| Emerging Markets · Licensing Agreements | 2,460.5 | 2,744.7 | -10.4% |
| Greater China · Licensing Agreements | 4,361.4 | 4,788.4 | -8.9% |
| JANZ · Licensing Agreements | 946.2 | 1,044.3 | -9.4% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Licensing Agreements | 14,396.1 | 16,256.6 | -11.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 15,102.1 | 17,070.9 | -11.5% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,754.1 | 1,853.7 | -5.4% |
| Accrued Income Taxes Current | 124 | 192.7 | -35.7% |
| Current Portion of Long-Term Debt | 1,933.3 | 8.3 | +23192.8% |
| Other Liabilities Current | 3,282.9 | 3,724.7 | -11.9% |
| Total Current Liabilities | 7,094.3 | 5,779.4 | +22.8% |
| Debt Current | 1,929.9 | 0.6 | +321550.0% |
Show Debt Instrument breakouts |
|||
| 2026 Senior Notes (3.950%) · Senior Notes | 1,674.3 | — | — |
| Other Current Portion of Long-term Debt | 1 | 0.6 | +66.7% |
| YEN Term Loan | 255.2 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 12,480.6 | 14,038.9 | -11.1% |
| Deferred Tax Liabilities | 892 | 1,107.9 | -19.5% |
| Other Non-Current Liabilities | 2,014.9 | 1,939.2 | +3.9% |
| Total Liabilities | 22,481.8 | 22,865.4 | -1.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Euro Senior Notes · Net Investment Hedging | 850 | — | — |
| 2027 Euro Senior Notes · Senior Notes | 1,011.5 | 899.4 | +12.5% |
| 2027 Senior Notes · Senior Notes | 758.6 | 764.2 | -0.7% |
| 2028 Euro Senior Notes · Senior Notes | 878.5 | 773.7 | +13.5% |
| 2028 Senior Notes · Net Investment Hedging | 750 | — | — |
| 2028 Senior Notes · Senior Notes | 749.5 | 749.3 | 0.0% |
| 2030 Senior Notes · Senior Notes | 1,488.8 | 1,497 | -0.5% |
| 2032 Euro Senior Notes · Net Investment Hedging | 1,250 | — | — |
| 2032 Euro Senior Notes · Senior Notes | 1,549.2 | 1,376.2 | +12.6% |
| 2040 Senior Notes · Senior Notes | 1,630.1 | 1,637.1 | -0.4% |
| 2043 Senior Notes (5.400%) · Senior Notes | 497.6 | 497.5 | 0.0% |
| 2046 Senior Notes (5.250%) · Senior Notes | 999.9 | 999.9 | 0.0% |
| 2048 Senior Notes · Senior Notes | 747.9 | 747.9 | 0.0% |
| 2050 Senior Notes · Senior Notes | 2,186.8 | 2,191.6 | -0.2% |
| Other Long Term Debt | 2.7 | 2.2 | +22.7% |
| YEN Term Loan · Net Investment Hedging | 40,000 | — | — |
Show Derivative Risk breakouts |
|||
| Net Investment Hedging | 2,850 | — | — |
| Operating Lease Liabilities | 178.1 | 179.3 | -0.7% |
| Stockholders' Equity | |||
| Common Stock | 12.5 | 12.3 | +1.6% |
| Additional Paid-In Capital | 18,801.3 | 18,921.6 | -0.6% |
| Retained Earnings | -388.3 | 3,418.8 | -111.4% |
| Accumulated Other Comprehensive Income | -2,707 | — | — |
| Stockholders Equity Parent Before Treasury Stock | 15,718.5 | 19,139.8 | -17.9% |
| Treasury Stock Value | 1,007.2 | 504.3 | +99.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 14,711.3 | 18,635.5 | -21.1% |
Show Equity Components breakouts |
|||
| Additional Paid In Capital | 18,801.3 | 18,921.6 | -0.6% |
| Common Stock | 12.5 | 12.3 | +1.6% |
| Retained Earnings | -388.3 | 3,418.8 | -111.4% |
| Treasury Stock Common | 1,007.2 | 504.3 | +99.7% |
| Total Liabilities & Equity | 37,193.1 | 41,500.9 | -10.4% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 279.6 | 254.2 | +10.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -3.1 | 32.3 | -109.6% |
| Accumulated Net Unrealized Investment Gain Loss | -0.4 | -1.2 | +66.7% |
| Accumulated Other Comprehensive Income | -2,707 | -3,212.9 | +15.7% |
| Accumulated Translation Adjustment | -3,088.2 | -3,990.8 | +22.6% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | 105.1 | 492.6 | -78.7% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 2,798.3 | 2,893.2 | -3.3% |
| Deferred Income Taxes | -476.5 | -767.6 | +37.9% |
| Changeinnoncashlitigationsettlementsnet | -40.2 | 274.5 | -114.6% |
| Gain Loss On Sale Of Business | 101 | 399.5 | -74.7% |
Show Disposal Group Classification breakouts |
|||
| Disposal Group Held For Sale Or Disposed Of By Sale Not Discontinued Operations · Other Nonoperating Income Expense | 101 | — | — |
| Stock-Based Compensation | 177.7 | 146.1 | +21.6% |
| Payments To Acquire In Process Research And Development Other | 50.8 | 12.3 | +313.0% |
| Other Non-Cash Items | 969.3 | -23.3 | +4260.1% |
| Change in Accounts Receivable | 334.6 | 300.1 | +11.5% |
| Change in Inventory | -106.4 | -723.4 | +85.3% |
| Increase Decrease In Accounts Payable Trade | -168 | 36 | -566.7% |
| Increase Decrease In Accrued Income Taxes Payable | -112.9 | 219.3 | -151.5% |
| Increase Decrease In Other Operating Capital Net | -633.7 | -150.6 | -320.8% |
| Net Cash from Operations | 2,315.9 | 2,302.9 | +0.6% |
| Investing Activities | |||
| Capital Expenditures | -378.8 | -326 | -16.2% |
| Other Investing Activities | -35.5 | -20.8 | -70.7% |
| Proceeds From Sale Of Property Plant And Equipment | 34.9 | 2.7 | +1192.6% |
| Proceeds From Refund Of In Process Research And Development | -50.8 | -12.3 | -313.0% |
| Proceeds From Divestiture Of Businesses | 2.5 | 2,507.1 | -99.9% |
| Payments To Acquire Marketable Securities | -23.9 | -26 | +8.1% |
| Proceeds From Sale And Maturity Of Marketable Securities | 23.9 | 26 | -8.1% |
| Net Cash from Investing | -427.7 | 1,800.7 | -123.8% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -0.1 | -3,713.7 | +100.0% |
| Payments Of Financing Costs | -1.5 | -4.8 | +68.8% |
| Proceeds From Repayments Of Short Term Debt | 0.2 | — | — |
| Share Repurchases | -500.5 | -250 | -100.2% |
| Tax Withholding for Share Compensation | -30.2 | -53.3 | +43.3% |
| Payments Of Merger Related Costs Financing Activities | -13.1 | -31.5 | +58.4% |
| Payments To Minority Shareholders | -561.2 | -574.8 | +2.4% |
| Proceeds From Issuance Of Common Stock | 2.6 | 2.5 | +4.0% |
| Proceeds From Payments For Other Financing Activities | -190.1 | 295.2 | -164.4% |
| Net Cash from Financing | -1,293.9 | -4,330.4 | +70.1% |
| Supplemental | |||
| Interest Paid | 492.6 | 561.1 | -12.2% |
| Income Taxes Paid | 445.4 | — | — |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 17.6 | -30.7 | +157.3% |
| Net Change in Cash | 611.9 | -257.5 | +337.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,348 | 736.1 | +83.1% |
Values in millions USD. Source: SEC EDGAR 10-K filing.